[1]秦 瑶,杜 玉,祝 琳,等.利多卡因在奥沙利铂肝动脉灌注化疗中的止痛作用及配伍稳定性与护理探讨[J].介入放射学杂志,2026,(02):161-164.[doi:10.3969/j.issn.1008-794X.2026.02.008 ]
　QIN Yao,DU Yu,ZHU Lin,et al.Evaluation of the analgesic effect and compatibility stability of lidocaine in hepatic arterial infusion chemotherapy with oxaliplatin and discussion of the nursing care[J].J Intervent Med,2026,(02):161-164.[doi:10.3969/j.issn.1008-794X.2026.02.008 ]
点击复制

利多卡因在奥沙利铂肝动脉灌注化疗中的止痛作用及配伍稳定性与护理探讨()

PDF下载中关闭

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2026年02
页码:
161-164
栏目:
肿瘤介入
出版日期:
2026-02-25

文章信息/Info

Title:
Evaluation of the analgesic effect and compatibility stability of lidocaine in hepatic arterial infusion chemotherapy with oxaliplatin and discussion of the nursing care
文章编号:
1008-794X(2026)-002-0161-04
作者:
秦 瑶;  杜 玉;  祝 琳;  傅 蓉;  李亦栋;  沈梦蕾;  顾晓华;  王 颖;  马婧嶔;  颜志平;  瞿旭东
通信作者: 马婧嶔 E-mail:ma.jingqin@zs-hospital.sh.cn
Author(s):
QIN Yao1; DU Yu1; ZHU Lin1; FU Rong1; LI Yidong1; SHEN Menglei1; GU Xiaohua1; WANG Ying1; MA Jingqin2; YAN Zhiping2; QU Xudong2.
1Department of Interventional Therapy Nursing,Affiliated Zhongshan Hospital of Fudan University,Shanghai 200032,China; 2Shanghai Institution of Medical Imaging,Shanghai 200032,China
关键词:
利多卡因;  奥沙利铂;  止痛;  配伍稳定性;  护理干预
分类号:
R735.7
DOI:
10.3969/j.issn.1008-794X.2026.02.008
文献标志码:
A
摘要:
目的 探究利多卡因在奥沙利铂肝动脉灌注化疗(hepatic artery infusion chemotherapy,HATC)中的止痛作用及配伍稳定性与护理干预对患者疼痛管理的效果。方法 纳入2024年2月至2024年9月复旦大学附属中山医院行HAIC治疗的原发性肝癌患者200例。根据利多卡因的不同剂量将患者随机分为4组,25 mg组、50 mg组、100 mg组与对照组(仅用奥沙利铂),每组50例。通过视觉模拟评分法(VAS)评估疼痛,检测药物配伍稳定性,并实施护理干预。结果 奥沙利铂+50 mg利多卡因组镇痛效果最佳,配伍稳定性良好,护理干预显著改善患者疼痛管理。结论 利多卡因可有效缓解奥沙利铂HAIC引起的疼痛,50 mg为最佳选择,护理干预对疼痛管理具有积极意义。

参考文献/References:

[1] 张 正,张莉芳,刘彦廷,等.《2022全球癌症统计报告》解读[J].中国医院统计,2024,31,5:393-400. Zhang Z,Zhang LF,Liu YT,et al.Interpretation of “2022 Global Cancer Statistics Report”[J].Chinese Journal of Hospital Statistics,2024,31,5:393-400. [2]Zhao M,Guo Z,Zou YH,et al.Arterial chemotherapy for hepatocellular carcinoma in China:consensus recommendations[J].Hepatol Int,2024,18:4-31. [3]滕金豪,俞 渊,潘 孟,等.mFOLFOX-HAIC联合靶向及免疫治疗对巨块型肝细胞癌的临床疗效[J].江苏医药,2024,50,5:530-533. Teng JH,Yu Y,Pan M,et al.Clinical efficacy of mFOLFOX-HAIC combined with targeted and immunotherapy in the treatment of massive hepatocellular carcinoma[J].Jiangsu Medicine,2024,50,5:530-533. [4]Werdehausen R,Braun S,Hermanns H,et al.The influence of adjuvants used in regional anesthesia on lidocaine-inducedneurotoxicity in vitro[J].Reg Anesth Pain Med,2011,36,5:436-443. [5]Kaba A,Laurent S R,Detroz B J,et al.Intravenous lidocaine infusion facilitates acuterehabilitation after laparoscopic colectomy[J].Anesthesiology,2007,106,1:11-18. [6]Liver Cancer Committee of the Chinese Anti-Cancer Association.Chinese Expert Consensus on Hepatocellular Carcinoma Treated with Hepatocellular Artery Infusion Chemotherapy(2021 Edition)[J].Chinese Journal of Digestive Surgery,2021,20,7:754-759. [7]杜 楠,王 英,李文涛.肝癌TACE还是HAIC[J].介入放射学杂志,2024,33,12:1269-1273. Du N,Wang Y,LI Wen T.Treatment of hepatocellular carcinoma:TACE or HAIC?[J].J Intervent Radiol,2024,33,12:1269-1273. [8]Tan Y,Li T,Wang R,et al.WTAP weakens oxaliplatin chemosensitivity of colorectal cancer by preventing PANoptosis[J].Cancer Lett,2024,604:217254. [9]Chubykina S V,Tatarinova MU,Avakyan GG.Neuropathic pain caused by the toxic effect of chemotherapy in patients with malignant neoplasms[J].Zh Nevrol Psikhiatr Im S S Korsakova,2023,123,5:7-12. [10]Marcotti A,Fernandez-Trillo J,Gonzalez A,et al.TRPA1 modulation by Sigma-1 receptor prevents oxaliplatin-induced painful peripheral neuropathy[J].Brain,2023,146,2:475-491. [11]Wu Z,Guo W,Chen S,et al.Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy[J].Invest New Drugs,2021,39:394-399. [12]Zhang R,Liao Y,Yang X,et al.Effect of lidocaine pumped through hepatic artery to relieve pain of hepatic artery infusion chemotherapy[J].Front Surg,2024,11:1378307. [13]Fallon M,Giusti R,Aielli F,et al.Management of cancer pain in adult patients:ESMO clinical practice guidelines[J].Ann Oncol,2018,29:iv166-iv191. (收稿日期:2025-04-14) (本文编辑:新 宇)

相似文献/References:

[1]高 嵩,朱旭,杨仁杰,等. ＴＡＣＥ联合奥沙利铂、氟尿嘧啶、亚叶酸钙肝动脉化疗治疗中晚期原发性肝癌[J].介入放射学杂志,2012,(05):377.
　,,et al. ＴＡＣＥ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｈｅｐａｔｉｃ ａｒｔｅｒｉａｌ ｉｎｆｕｓｉｏｎ ｃｈｅｍｏｔｈｅｒａｐｙ ｕｓｉｎｇ ｏｘａｌｉｐｌａｔｉｎ， ５ｆｌｕｏｒｏｕｒａｃｉｌ ａｎｄ ｆｏｌｉｎｉｃ ａｃｉｄ ｆｏｒ ｉｎｔｅｒｍｅｄｉａｔｅ ａｎｄ ａｄｖａｎｃｅｄ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ[J].J Intervent Med,2012,(02):377.
[2]储玉山,朱小庆,张玉宇,等.索拉非尼联合奥沙利铂对肝癌ＨｅｐＧ２细胞的抑制作用[J].介入放射学杂志,2011,(10):810.
　CHU Yu-shan,ZHU Xiao-qing,ZHANG Yu-yu,et al. The inhibitory effect of sorafenib together with oxaliplatin on the growth of human hepatic carcinoma cell line HepG2 in vitro[J].J Intervent Med,2011,(02):810.
[3]王少雷,李 森,魏 宏,等.奥沙利铂与吡喃阿霉素介入治疗原发性肝癌的比较研究[J].介入放射学杂志,2012,(09):738.
　WANG Shao- lei,LI Sen,WEI Hong,et al. Interventional chemoembolization therapy of primary hepatocellular carcinoma： a comparative study between oxaliplatin and therarubicin[J].J Intervent Med,2012,(02):738.
[4]颜 鹏,方志勇,向 华.奥沙利铂及重组人血管内皮抑素经肝动脉灌注联合TACE治疗原发性肝癌[J].介入放射学杂志,2013,(02):121.
　YAN Peng,FANG Zhi? yong,XIANG Hua..Transhepatic arterial infusion of oxaliplatin and recombinant human endostatin combined with TACE for primary hepatocellular carcinoma[J].J Intervent Med,2013,(02):121.
[5]刘学芬,彭东,李刚,等.吉西他滨和奥沙利铂栓塞化疗联合三维适形放疗治疗晚期原发性肝癌疗效观察[J].介入放射学杂志,2013,(04):292.
　LIU Xue? fen,PENG Dong,LI Gang,et al.Transcatheter arterial chemoembolization with regimen GEMOX together with three?蛳 dimensional conformal radiotherapy for advanced primary hepatocellular carcinoma： a clinical observation[J].J Intervent Med,2013,(02):292.
[6]乔彬彬,虞希祥,王舒婷,等.TACE术中灌注氟尿嘧啶、奥沙利铂及吡柔比星治疗原发性肝癌的临床效果分析[J].介入放射学杂志,2015,(04):349.
　QIAO Bin bin,YU Xi xiang,WANG Shu ting,et al.TACE with infusion of fluorouracil， oxaliplatin and pirarubicin for the treatment of primary liver cancer： analysis of clinical effect[J].J Intervent Med,2015,(02):349.
[7]黄 芳,龚环宇,熊正平.雷替曲塞联合奥沙利铂TACE治疗BCLC B/C期肝细胞癌的安全性及疗效[J].介入放射学杂志,2018,27(01):76.
　HUANG Fang,GONG Huanyu,XIONG Zhengping.The safety and efficacy of raltitrexed combined with oxaliplatin in TACE treatment for BCLC B/C hepatocellular carcinomas[J].J Intervent Med,2018,27(02):76.
[8]王天成,马聪,肖煜东,等.利多卡因-表阿霉素-超液化碘油混合乳剂在肝癌TACE相关疼痛管理中的应用 [J].介入放射学杂志,2020,29(04):366.
　WANG Tiancheng,MA Cong,XIAO Yudong,et al.The application of lidocaine-epirubicin-lipiodol emulsion in the management of TACE-related pain in HCC patients[J].J Intervent Med,2020,29(02):366.
[9]杨　钦,程芝梅,王黎洲,等.利多卡因-表柔比星-超液化碘油混合乳剂在体外及兔肝癌模型中缓释效果的研究[J].介入放射学杂志,2023,32(01):43.
　YANG Qin,CHENG Zhimei,WANG Lizhou,et al.The slow-release effect of lidocaine-epirubicin-superliquefied lipiodol mixed emulsion in vitro and in rabbit liver cancer models[J].J Intervent Med,2023,32(02):43.
[10]刘 平,马晓晓,刘宝将,等.82例肝动脉灌注化疗致过敏反应患者的临床特征及护理对策[J].介入放射学杂志,2023,32(12):1242.
　LIU Ping,MA Xiaoxiao,LIU Baojiang,et al.Clinical features of patients with allergic reactions induced by hepatic arterial perfusion chemotherapy and its nursing strategy： preliminary results in 82 patients[J].J Intervent Med,2023,32(02):1242.

备注/Memo

备注/Memo:
通信作者: 马婧嶔 E-mail:ma.jingqin@zs-hospital.sh.cn
更新日期/Last Update: 2026-02-25